CFTR and cystic fibrosis: While these effect estimates decreased slightly from the primary analysis, this is likely explained by such control patients having more severe disease on average: most of the identified CF carriers were tested in the course of pregnancy, whereas controls tested for “suspected CFTR mutations” are generally tested in response to recurrent CF-related conditions.